Captor Therapeutics S.A. Logo

Captor Therapeutics S.A.

Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.

CTX | WAR

Overview

Corporate Details

ISIN(s):
PLCPTRT00014 (+1 more)
LEI:
259400JHH1S2I2S4O735
Country:
Poland
Address:
Wrocław Duńska 11, 54-427 Wrocław
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Captor Therapeutics S.A. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapeutics using Targeted Protein Degradation (TPD) technology. The company focuses on creating breakthrough, first-in-class treatments for high unmet medical needs, particularly in oncology and autoimmune diseases. Its core is the proprietary Optigrade™ drug discovery platform, which leverages multidisciplinary expertise in protein engineering, structural biology, and molecular modelling. This integrated approach enables the company to address previously "undruggable" molecular targets, accelerating the development of drug candidates with the potential to significantly impact patient outcomes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-27 13:41
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających na Nadzwyczajnym Walnym Zgromadzeniu Spółki …
Polish 2.0 KB
2025-10-24 18:29
Regulatory News Service
Zawarcie umowy z Europejską Radą ds. Innowacji i Agencją Wykonawczą ds. MŚP (EI…
Polish 1.3 KB
2025-10-22 17:51
Post-Annual General Meeting Information
treść uchwał
Polish 465.8 KB
2025-10-22 17:51
Post-Annual General Meeting Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie 22 października 20…
Polish 1.2 KB
2025-10-15 15:25
Post-Annual General Meeting Information
projekt uchwały
Polish 167.2 KB
2025-10-15 15:25
Pre-Annual General Meeting Information
Zgłoszenie przez Akcjonariusza projektu uchwały w sprawie objętej porządkiem ob…
Polish 1.1 KB
2025-10-14 18:11
Share Issue/Capital Change
Zakończenie subskrypcji akcji serii W emitowanych w związku z realizacją progra…
Polish 4.1 KB
2025-09-30 13:20
Director's Dealing
załącznik do raportu
Polish 4.3 KB
2025-09-30 13:20
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 398 bytes
2025-09-30 13:10
Director's Dealing
Załącznik do raportu
Polish 4.3 KB
2025-09-30 13:10
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 566 bytes
2025-09-30 12:53
Director's Dealing
Załącznik do raportu
Polish 4.3 KB
2025-09-30 12:53
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 543 bytes
2025-09-29 16:32
Director's Dealing
Załącznik do raportu
Polish 4.4 KB
2025-09-29 16:32
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 653 bytes

Automate Your Workflow. Get a real-time feed of all Captor Therapeutics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Captor Therapeutics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Captor Therapeutics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea 244460
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea 382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea 476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan 4564
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France ALONX
Openedges Technology, Inc. Logo
Semiconductor IP provider of memory subsystem & AI platform IP for AI, HPC, and IoT SoCs.
South Korea 394280
Openjobmetis Logo
Employment agency providing staffing, recruitment, and HR services to companies and job seekers.
Italy OJM
Open Up Group Inc. Logo
Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.
Japan 2154

Talk to a Data Expert

Have a question? We'll get back to you promptly.